{
    "id": "correct_award_00039_0",
    "rank": 73,
    "data": {
        "url": "https://www.oncotarget.com/editorial-board/",
        "read_more_link": "",
        "language": "en",
        "title": "The Editors-in-chief & Editorial Board Members of Oncotarget",
        "top_image": "https://www.oncotarget.com/images/meta/editorial-board-editors.png",
        "meta_img": "https://www.oncotarget.com/images/meta/editorial-board-editors.png",
        "images": [
            "https://www.oncotarget.com/public/journals/1/cover_issue_520_en_US.png",
            "https://www.oncotarget.com/images/oncotarget-org-cropped.png",
            "https://www.oncotarget.com/images/oncotarget-net-cropped.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "open access journal",
            "cancer research",
            "impact journal",
            "impact factor",
            "pub-med"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Learn about the current Oncotarget Editors-in-Chief and Editorial Board Members",
        "meta_lang": "en",
        "meta_favicon": "/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://www.oncotarget.com/editorial-board/",
        "text": "Editors-in-Chief\n\nWafik S. El-Deiry Brown University, Providence, RI\n\nWafik S. El-Deiry, MD, PhD, FACP\n\nAmerican Cancer Society Research Professor\n\nDirector, Legorreta Cancer Center at Brown University\n\nAssociate Dean, Oncologic Sciences\n\nWarren Alpert Medical School, Brown University\n\nChair, WIN Consortium for Personalized Cancer Medicine\n\nAndrei V. Gudkov Roswell Park Comprehensive Cancer Center, Buffalo, NY\n\nAndrei V. Gudkov, PhD, DSci, Professor and Garman Family Chair in Cell Stress Biology, Senior Vice President for Basic Research of Roswell Park Comprehensive Cancer Center (RPCI), Buffalo, NY. His academic degrees in experimental oncology and molecular biology were received in former USSR from National Cancer Center and Moscow State University. He is co-founder and Chief Scientific Officer of Cleveland BioLabs, Inc. and Tartis, Inc. His area of general research interest includes drug discovery, gene discovery, molecular targets for cancer treatment.\n\nMikhail V. Blagosklonny Roswell Park Comprehensive Cancer Center, Buffalo, NY\n\nMikhail V. Blagosklonny, M.D., Ph.D., Professor, Roswell Park Comprehensive Cancer Center, Buffalo, NY\n\nDr. Blagosklonny is author of over 200 articles in peer-reviewed journals. He is Associate Editor of Cancer Res, Cell Death Differ, Cancer Biol Ther, Autophagy, Int J Cancer, Am J Pathology, PLOS ONE and Editor-in-Chief of Cell Cycle. His research interests range from molecular and cellular biology to clinical investigations and include signal transduction, cell cycle, cellular senescence, anticancer therapeutics with emphasis on translation of basic science into new anticancer strategies Recently, he extended the study of signal transduction pathways from cancer to aging, revealing potential targets for slowing down aging and age-related diseases.\n\nEditorial Board\n\nCory Abate-Shen Columbia University, New York, NY\n\nCory Abate-Shen, PhD, Professor, Director of Research, Department of Pathology, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University, NY\n\nFrederick Alt Harvard Medical School, Boston, MA\n\nFrederick W. Alt, Ph.D., member of the National Academy of Sciences, Professor, Harvard Medical School\n\nDr. Alt is also Investigator, Howard Hughes Medical Inst., Charles A. Janeway Professor of Pediatrics, HMS, Scientific Director, CBRI Institute for Biomedical Research.Fred Alt received a PhD from the Department of Biological Sciences at Stanford University. He is a Howard Hughes Medical Institute investigator, a member of the National Academy of Sciences and the American Academy of Sciences. He is the recipient of He is the recipient of the 2003 Excellence in Mentoring Award from the American Association of Immunologists and the 2004 Clowes Memorial Award from the American Association of Cancer Research. Editorial Boards: Mol. and Cell. Biology; Advances in Immunology; International Immunology; J. Exp. Med.; Current Opinion in Immunology; Immunity (founding Co-editor; 1993-present); Molecular Medicine (Contributing editor; 1997-present); Faculty of 1000 (co-head, Immunology). Honors and Awards: Fox Award, Stanford Univ. (1973); Hirschl Award (1983); Searle Scholar; (1983) Mallinckrodt Scholar; (1984); NIH Merit Award (1991); National Academy of Sciences (1994); American Academy of Microbiology (1994); American Academy of Arts and Sciences (1994); Associate (Foreign) Member, European Molecular Biology Organization (1999); Excellence in Mentoring Award,Association of Immunologists (2003); American Association of Cancer Research B.H.A. Clowes Award (2004); Rabi Shai Shacknai Memorial Prize in Immunology & Cancer Research (2005); Leukemia & Lymphoma Society de Villiers International Achievement Award (2005), Pasarow Foundation Prize in Cancer Research (2005); Irvington Institute Scientific Leadership in Immunology Award (2005); Establishment of Frederick W. Alt Award for New Discoveries in Immunology by the Irvington Institute (2006); National Cancer Institute Alfred Knudson Award in Cancer Genetics(2007).\n\nDario Altieri Wistar Institute Cancer Center, Philadelphia, PA\n\nDario Altieri, MD, Robert and Penny Fox Distinguished Professor, Director, The Wistar Institute Cancer Center, Executive Vice President, Chief Scientific Officer, The Wistar Institute, Philadelphia, PA.\n\nDafna Bar-Sagi NYU School of Medicine, New York, NY\n\nDafna Bar-Sagi, Ph.D., Professor and Chair, Department of Biochemistry New York University School of Medicine, 550 First Avenue New York, NY 10016\n\nAfter earning her undergraduate and master's degree in Biochemistry from Bar-Ilan University in Israel, Dr. Bar-Sagi completed a PhD in Cell Biology at the State University of New York, Stony Brook (SUNY). She received postdoctoral training and eventually served as Senior Staff Investigator at Cold Spring Harbor Laboratory in Long Island. In 1995, she joined the faculty of the Department of Molecular Genetics and Microbiology at SUNY and served as Department Chair from 2003-2006. She relocated to New York University Medical Center in 2006, where she is currently Professor and Chair of the Department of Biochemistry. Dr. Bar-Sagi has published over 100 peer-reviewed articles in leading scientific journals. In 2008, she was appointed Chair of the Scientific Advisory Board of the Pancreatic Cancer Action Network.\n\nJiri Bartek Institute of Cancer Biology, Copenhagen, Denmark\n\nJiri Bartek, MD., Ph.D., Professor, Head, Department of Cell Cycle and Cancer Danish Cancer Society, Deputy Director, Centre for Genotoxic Stress Research Cancer Institute of Cancer Biology, Copenhagen\n\nHe received his M.D. degree from Palacky University in Olomouc, and his Ph.D. degree in Cell Biology from the Institute of Molecular Genetics in Prague, Czech Republic. His main research interests include the molecular mechanisms of mammalian cell-cycle control and responses to DNA damage, and the cancer-predisposing aberrations of these regulatory pathways.\n\nJiri Bartek has a total of more than 320 publications in peer reviewed journals (about 30-40 in Nature, Science and Cell), with over 26.000 citations. He is currently member of the editorial boards of 10 high-medium impact biomedical journals and has won a number of awards including: (1991,1992) Czech Medical Association Award, (2000) Elected EMBO member, (2002) A. Benzon Prize, (2003) Novo Nordisk Prize, (2003) G.J. Mendel Medal, (2006) Danish Cancer Society Prize\n\nStephen Baylin Johns Hopkins University, Baltimore, MD\n\nStephen B. Baylin, M.D., Professor, Deputy Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Virginia and DK Ludwig Professor of Oncology, Baltimore, MD, USA\n\nDr. Stephen B. Baylin is professor of oncology and medicine, director of the cancer biology program at the oncology center, and the Virginia and D.K. Ludwig Professor of Cancer Research at The Johns Hopkins University School of Medicine, and the associate director for research at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.\n\nDr. Baylin has been a member of committees of the American Cancer Society and the National Institutes of Health, and his multiple honors include a Research Career Development Award from the National Institutes of Health. For the last 20 years, Dr. Baylin has studied the role of epigenetic gene silencing in the initiation and progression of human cancer.\n\nMina J. Bissell Lawrence Berkeley National Laboratory, Berkeley, CA\n\nMina J. Bissell, PhD, member of the National Academy of Sciences, Distinguished Scientist, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkley, CA\n\nMina Bissell has been recognized for her lifetime contributions to the fields of breast cancer research, the enhanced role of extracellular matrix (ECM) and the nucleus environment to gene expression in normal and malignant tissues. These works have ushered and have changed some central paradigms that have strengthened the importance of context in the development of cancer.\n\nBruce Blazar University of Minnesota, Minneapolis, MN\n\nBruce R. Blazar, M.D., Professor, University of Minnesota, Minneapolis MN\n\nBruce R. Blazar is a Regents Professor of Pediatrics, and Chief of the Pediatric Blood and Marrow Transplantation Program. Dr. Blazar is the Director of the University of Minnesota's Clinical and Translational Science Institute.\n\nKenneth Cowan University of Nebraska Medical Center, Omaha, NE\n\nKenneth Cowan, M.D., Ph.D., Professor, University of Nebraska Medical Center, Omaha, NE, Director, Eppley Institute, Director, UNMC Eppley Cancer Center.\n\nDr. Cowan has authored more than 240 papers for scientific journals and has been appointed by President Bush to a six-year term on the National Cancer Advisory Board to help shape cancer policy.\n\nCarlo M. Croce The Ohio State University,Columbus, OH\n\nCarlo M. Croce, MD, Professor, member of the National Academy of Sciences, Director of Comprehensive Cancer Center, Chair, Molecular Virology, Immunology & Medical Genetics, The Ohio State University, Columbus, OH\n\nHonors & Awards\n\n1975 Research Career Development Award, The National Institutes of Health, Bethesda MD\n\n1985 Outstanding Investigator Award, National Institutes of Health, National Cancer Institute, Bethesda MD\n\n1987 Scientific Award, American Cancer Society, Philadelphia Division\n\n1990 Richard and Hinda Rosenthal Foundation Award, Association for Cancer Research\n\n1992 Eagles Fly for Leukemia Lifetime Achievement Award\n\n1992 Scanno Prize for Medicine\n\n1992 Outstanding Investigator Award, National Institutes of Health, National Cancer Institute, Bethesda MD\n\n1993 Charles S. Mott Prize, General Motors Cancer Research Foundation\n\n1993 John Scott Award\n\n1994 Robert J. and Claire Pasarow Foundation Cancer Award\n\n1994 Honorary Member, Japanese Cancer Association\n\n1995 CLAS Distinguished Scientist Award\n\n1996 National Academy of Sciences\n\n1997 Rudolf Virchow Honorary Lectureship, University of Wurzburg, Germany\n\n1997 Scientific Excellence in Medicine Award, American-Italian Cancer Foundation\n\n1997 The Twenty-Fifth Solomon A. Berson Memorial Lecture, Mt. Sinai School of Medicine, NY\n\n1999 Raymond Bourgine Award and Gold Medal of Paris\n\n1999 AACR-Pezcoller International Award for Cancer Research, American Association for Cancer Research\n\n1999 Herz Memorial Lecture in Cancer Research, Tel Aviv University\n\n2000 Doctor in Medicine, Honoris Causa, Uppsala University, Sweden\n\n2000 Honor of Merit of Italian Republic\n\n2001 Clavius Award for Achievement in Science and Research\n\n2002 Rod and Ceil Mortel Lecture in Cancer Research, Penn State University\n\n2003 Italian Gold Medal for Public Health, Presented by President Ciampi\n\n2003 President of the Republic Prize, Accademia di Lincei\n\n2003 Golgi Lecture, Accademia Nazionale dei Lincei\n\n2003 Foreign Member, Accademia Nazionale delle Scienze, delta dei XL\n\n2004 Premio Beccaria, A. Serra Foundation for Cancer Research\n\n2005 Gottlieb Award, MD Anderson Cancer Center\n\n2006 G.H.A. Clowes Memorial Award, American Association for Cancer Research\n\n2007 The iwCLL Binet-Rai-Medal for Outstanding Contribution to CLL Research\n\n2007 The Henry M. Stratton Medal, American Society of Hematology (ASH)\n\n2008 Albert Szent-Györgyi Prize for Progress in Cancer Research\n\n2008 ARC Léopold Griffuel Prize for a Major Breakthrough in the Field of Cancer\n\n2009 Maud L. Menten Endowed Lectureship, University of Pittsburgh\n\n2009 Orrin Ingram Distinguished Lecture, Vanderbilt-Ingram Cancer Center\n\n2010 The Ernst W. Bertner Memorial Award, The University of Texas M. D. Anderson Cancer Center\n\n2010 Fellow of the American Academy of Arts and Sciences\n\n2010 George and Lily Boxer Memorial Lecture, Robert Wood Johnson Medical School\n\n2010 Annual Nickerson Memorial Lecture, McGill University, Montreal, Canada\n\n2011 AMP Award for Excellence in Molecular Diagnostics 2011\n\n2011 Fellow, American Association of Physicians\n\n2011 Member, Institute of Medicine (IOM) of the National Academies\n\n2011 AAAS Fellow, American Association for the Advancement of Science\n\n2011 Weinman Foundation Innovation Fund Recipient, University of Hawaii Cancer Center\n\n2012 Anthony Dipple Carcinogenesis Award, European Association of Cancer Research\n\n2012 W. E. Keck Distinguished Lecture, W.E. Keck Center for Innovative Cancer Therapies, M. D. Anderson Cancer Center\n\n2012 Sebetia–Ter Award International Prize, Naples, Italy\n\n2013 Foreign Member, Accademia delle Scienze dell’Istituto di Bologna, Bologna, Italy\n\n2013 Recipient of the 2013 AACR Princess Takamatsu Memorial Lectureship, American Association for Cancer Research\n\n2013 Inaugural AACR Fellow of the Academy of the American Association for Cancer Research\n\n2013 Health Prize of the Fund InBev-Baillet Latour, Leuven, Belgium\n\n2013 The Eliezer Flescher Memorial Lecture, The Israeli Society for Cancer Research\n\n2013 ICCNS – Springer Award, Nice France\n\n2013 Juckett Distinguished Lecture – Vermont Cancer Center, University of Vermont\n\n2013 Fellow of the National Academy of Inventors\n\n2013 Distinguished Lecture – Frontiers in Oncology, Continuum Cancer Centers of New York and Beth Israel St. Lukes-Roosevelt Medical Centers\n\n2014 Chauncey D. and Elizabeth W. Leake 2014 Speaker Award\n\n2014 Janet Rowley Memorial Lecture, American Association for Cancer Research, Philadelphia, PA\n\n2015 Beckman Research Institute/Art Riggs Lectureship, City of Hope, Pasadena, CA\n\n2015 Outstanding Investigator Award, National Cancer Institute\n\n2016 Donald S. Coffey Lecturer, Soc. for Basic Urologic Research (SBUR) and the Soc. Of Urologic Oncology (SUO) Joint Society Meeting, San Diego, CA\n\n2017 Margaret Foti Award, American Association for Cancer Research (AACR)\n\nChi Van Dang Johns Hopkins University, Baltimore, MD\n\nChi Van Dang, M.D., Ph.D. Professor, Vice Dean for Research, the Johns Hopkins University School of Medicine, Baltimore, MD\n\nDr. Dang has written more than 200 scientific papers. He is senior editor of Cancer Research and serves on the editorial boards of eight other scientific publications, including the Journal of Molecular Medicine, Current Cancer Therapy Reviews, Drug Discovery Today: Disease Mechanisms, Journal of Clinical Investigations, Neoplasia, Clinical and Translational Science and The Vietnamese Medical Journal. Elected to the National Academy of Sciences' Institute of Medicine in 2006, Dr. Dang has received the National Institutes of Health/National Cancer Institute MERIT award and numerous other accolades.\n\nRonald A. DePinho MD Anderson Cancer Center, Houston, TX\n\nDePinho, MD, Member of the National Academy of Sciences, Past President, The University of Texas MD Anderson Cancer Center, Houston, TX, and Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.\n\nHis recent Awards includes Albert Szent-Gyrgyi Prize for Progress in Cancer Research, 2009; Helsinki Medal, 2007; Albert Einstein College of Medicine Distinguished Alumnus Award, 2004; American Cancer Society Edith A. Pistorino Research Professorship, 2004; Member, Institute of Medicine of the National Academies, 2004; AACR-G.H.A. Clowes Memorial Award, 2003\n\nBrian J. Druker Oregon Health Science University, Portland, OR\n\nBrian J. Druker, MD, PhD, member of the National Academy of Sciences, Professor, Oregon Health & Science University, Director, OHSU Knight Cancer Institute, Oregon Health & Science University\n\nDr. Druker is the director of OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, and professor of medicine. In 2009 he won the Lasker Clinical Award and the Meyenburg Cancer Research Prize for his influential work in the development of STI571, commonly known as Gleevec, for the treatment of Chronic Myeloid Leukemia. Dr. Druker is an investigator of Howard Hughes Medical Institute (HHMI), and was elected to the Institute of Medicine of National Academies in 2003, the American Association of Physician in 2006, and the National Academy of Sciences in 2007.\n\nMichael A. Dyer St. Jude Children's Research Hospital, Memphis, TN\n\nMichael A. Dyer, PhD, Professor/Member, St. Jude Faculty Co-Leader, Developmental Therapeutics for Solid Malignancies Program\n\nAndrew Feinberg Johns Hopkins University School of Medicine, Baltimore, MD\n\nAndrew Feinberg, MD, MPH, King Fahd Professor of Molecular Medicine Department of Medicine, Department of Oncology and Department of Molecular Biology & Genetics, Johns Hopkins University School of Medicine\n\nDean W. Felsher Stanford University School of Medicine, Stanford, CA\n\nDean W. Felsher, MD, PhD, Stanford University School of Medicine, Stanford, CA\n\nAntonio Giordano Temple University, Philadelphia, PA\n\nAntonio Giordano, MD, Ph.D, Professor and Director, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA\n\nHe has published over 350 papers on his work in the fields of cell cycle, gene therapy and the genetics of cancer. Giordano has been named a Knight of the Republic of Italy for outstanding achievements in cancer research. In September of 2009, Giordano received the Philip Mazzei \"The Bridge\" Award from The American University of Rome for his scientific and economic contributions to the United States and Italy. In the past three years, Dr. Giordano's work has been profiled in Philadelphia Magazine, Philadelphia Business Journal, and Science.\n\nCandace S Johnson Roswell Park Comprehensive Cancer Center, Buffalo, NY\n\nPresident & CEO of Roswell Park Comprehensive Cancer Center, the Wallace Family Chair in Translational Research, and Professor of Oncology.\n\nMichael Karin University of California, Los Angeles, CA\n\nMichael Karin, Ph.D, member of the National Academy of Sciences, Professor of Pharmacology at the University of California, San Diego (UCSD; La Jolla, CA)\n\nDr. Karin has received numerous awards including the Oppenheimer Award for Excellence in Research from the Endocrine Society, The Herman Beerman Lectureship from the Society of Investigative Dermatology, C.E.R.I.E.S. Research Award for Physiology or Biology of the Skin, The Grossman Lectureship form the American Gastroenterology Association and an American Cancer Society Research Professorship in 1999. Dr. Karin was elected to the National Academy of Sciences in 2005. Dr. Karin also serves on several advisory boards and was cofounder of Signal Pharmaceuticals (currently Celgene).\n\nScott E. Kern Johns Hopkins University, Baltimore, MD\n\nScott E. Kern, M.D., Professor of Oncology, Johns Hopkins University, Baltimore, MD, co-director of the Kimmel Cancer Center Gastrointestinal Cancer Program, Everett and Marjorie Kovler Professor of Pancreas Cancer Research.\n\nDr. Kern is a molecular geneticist interested in the clonal mutations of cancer, especially pancreatic cancer. His laboratory identified the first human Smad gene, SMAD4, as well as the first cancer mutations in Smad4, BRCA2, and other genes. Current interests include pharmacogenomics, mitotic instability, and the clinical significance of cancer biomarkers.\n\nGuido Kroemer Research Director, INSERM, Paris, France\n\nGuido Kroemer, Professor, Faculty of Medicine of the University of Paris Descartes, Director of the research team \"Apoptosis, Cancer and Immunity\" of the French Medical Research Council (INSERM).\n\nJohn S. Lazo UVA Cancer Center, Charlottesville, VA\n\nJohn S. Lazo, PhD, Harrison Distinguished Professor, Departments of Pharmacology & Chemistry, Associate Director for Basic Science, UVA Cancer Center; Adjunct Professor Virginia Tech Carilion Research Institute\n\nArnold Levine Institute for Advanced Study, Princeton, NJ\n\nArnold J. Levine, Ph.D. Member of the National Academy, Professor, The Simons Center for Systems Biology in the School of Natural Sciences at the Institute for Advanced Study, Princeton, NJ.\n\nLevine was on the faculty of the Biochemistry Department of Princeton University from 1968 to 1979, when he became chair and professor in the Department of Microbiology at the State University of New York, Stony Brook, School of Medicine. Returning to Princeton University in 1984, he was named Harry C. Wiess Professor in the Life Sciences in the Department of Molecular Biology, a position he held until 1998. He chaired the Department between 1984 and 1996. He was President and Chief Executive Officer of the Rockefeller University in New York City from 1998 to 2002, as well as Heilbrunn Professor of Cancer Biology and laboratory head until joining the Institute in 2002. The recipient of many honors including: the Medal for Outstanding Contributions to Biomedical Research from Memorial Sloan-Kettering Cancer Center (2000); the Keio Medical Science Prize of the Keio University Medical Science Fund, Japan (2000); the Albany Medical Center Prize in Medicine and Biomedical Research (2001); and the Award for Basic Research from the Surgical Society of Oncologists (2003). Levine is a member of the National Academy of Sciences and of the Academy's Institute of Medicine; he is also the author or coauthor of over 300 scientific papers, as well as a book, Viruses (1993). He has served as board member or adviser to numerous scientific organizations and educational institutions, among them the N.J. Biotechnology Institute, the American Cyanamid Corporation, the SUNY Health Sciences Center in Brooklyn, Albert Einstein College of Medicine, the Weizmann Institute,the Huntsman Cancer Center of the University of Utah, and the Institute for Cancer Research in Lausanne, Switzerland.\n\nMichael P. Lisanti University of Salford, Salford, UK\n\nProfessor Lisanti, M.D., Ph.D. serves as the Director of the Manchester Breakthrough Breast Cancer Research Unit and holds the Muriel Edith Rickman Chair of Breast Oncology within the Institute of Cancer Sciences. He is also Professor of Cancer Biology and the new founding Director of the Manchester Centre for Cellular Metabolism (MCCM).\n\nGerry Melino University of Rome, Rome , Italy\n\nDr. Melino is Full Professor of Molecular Biology at the University of Rome “Tor Vergata” in Italy. He also currently works as Programme Leader for the Medical Research Council Toxicology Unit, in Leicester, UK.\n\nHarold L. Moses Vanderbilt-Ingram Cancer Center, Nashville, TN\n\nHarold L. Moses, PhD, Professor, Vanderbilt-Ingram Cancer Center, Nashville, TN\n\nYusuke Nakamura University of Chicago, IL\n\nDr. Nakamura received his MD and PhD from Osaka University, and became Head of the Biochemistry Department, at the Cancer Institute, Japanese Foundation for Cancer Research in 1989. He was appointed as a professor at the Institute of Medical Science, University of Tokyo in 1994 and the Department of Medicine at the University of Chicago in 2012. From January to December 2011, Dr. Nakamura was Special Advisor to the Cabinet Secretary General, Office of Medical Innovation, Cabinet Secretariat, Government of Japan. Dr. Nakamura received the Keio Medical Science Prize and the Tomizo Yoshida Award of the Japanese Cancer Association. He is a member of the Association of American Physicians.\n\nDr. Yusuke Nakamura discovered the APC (Familial Adenomatous Polyposis) tumor suppressor. Dr. Nakamura plays the leading role in the field of personalized medicine. He authored 1200 scientific articles.\n\nJoseph Nevins Duke University, Durham, NC\n\nJoseph Nevins, PhD, Professor, Duke University, Durham, NC\n\nPier Paolo Pandolfi Harvard Medical School, Boston, MA\n\nPier Paolo Pandolfi, PhD, Professor, Harvard Medical School, Boston, MA\n\nGeorge C. Reisman Professor of Medicine and Professor of Pathology, Medicine, Harvard Medical School\n\nChief, Division of Genetics, Dept of Medicine, Beth Israel Deaconess Medical Center\n\nDirector, Cancer Center, Beth Israel Deaconess Medical Center\n\nDirector, Cancer Research Institute, Beth Israel Deaconess Medical Center\n\nNickolas Papadopoulos Johns Hopkins University, Baltimore, MD\n\nNickolas Papadopoulos, Ph.D. Associate Professor, Department of Oncology, Director of Translational Genetics, Ludwig Center for Cancer Genetics & Therapeutics, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Institutions, CRB1, Room 585, 1650 Orleans Street, Baltimore, MD 21231\n\nJeffrey Pollard Albert Einstein College of Medicine, Bronx, NY\n\nJeffrey Pollard, PhD, Professor, Albert Einstein College of Medicine, Bronx, NY\n\nCarol Prives Columbia University, New York, NY\n\nCarol Prives, Ph.D, member of the National Academy of Sciences, Professor, Columbia University, New York, NY\n\nEdward V. Prochownik Children's Hospital of Pittsburgh, Pittsburgh, PA\n\nEdward V. Prochownik, MD, PhD, Professor of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Director of Oncology Research, Children's Hospital of Pittsburgh, PA\n\nJohn C. Reed Roche Holding AG, Basel, Switzerland\n\nDr. John C. Reed, M.D., Ph.D. has been the Head of Roche Pharma Research & Early Development (Pred) at Roche Holding AG since April 2, 2013. He is an Adjunct professor at the University of California San Diego (UCSD) Department of Molecular Pathology, University of Florida, University of Central Florida, and in San Diego State University's Biology department.\n\nNeal Rosen Memorial Sloan-Kettering Cancer Center, New York, NY\n\nNeal Rosen, M.D., Ph.D. is a Member in the Department of Medicine and in the Molecular Pharmacology and Chemistry Program at Memorial Sloan-Kettering Cancer Center, where he serves as Head of Developmental Therapeutics. He is also a Professor of Pharmacology, Cell Biology and Medicine at Cornell University Medical School.\n\nAndrew V. Schally (Nobel Prize Laureate) Veterans Affairs Medical Center, Miami, FL\n\nAndrew V. Schally won the Nobel Prize for Medicine or Physiology in 1977, for his research into peptide hormone production in the brain. He is currently Distinguished Medical Research Scientist of the Department of Veterans Affairs, Head of the Endocrine, Polypeptide and Cancer Institute Veterans Affairs Medical Center, Research Service Miami, FL and South Florida VA Foundation for Research and Education, Distinguished Leonard Miller Professor of Pathology, Professor Division of Hematology/Oncology and Division of Endocrinology Department of Medicine, Miller School of Medicine, University of Miami, FL.\n\nDr. Schally was one of a pair of scientists to first isolate several of the communicating chemical links between the brain and the pituitary gland and also determined their structure and succeeded in synthesizing them. Schally’s discoveries have led to many practical clinical applications that are in wide use. He has written over 2,200 publications, more than 1,200 of them since receiving the Nobel Prize. 27 European & South American Universities: M.D.H.C., D.H.C., D.Sc.H.C., D.Nat. Sc. H.C.\n\nLasker Award 1975\n\nNobel Prize in Physiology or Medicine, 1977\n\nGregg L. Semenza (Nobel Prize Laureate) Johns Hopkins University, Baltimore, MD\n\nGregg L. Semenza, M.D., Ph.D, member of the National Academy of Sciences, Professor, Johns Hopkins University School of Medicine, Baltimore, MD\n\nDonald L. Trump Inova Schar Cancer Institute, Fairfax, VA\n\nDonald L. (Skip) Trump, MD, FACP, is CEO and executive director of Inova Schar Cancer Institute. Prior to joining Inova, Dr. Trump was president and CEO of Roswell Park Comprehensive Cancer Center in Buffalo, NY.\n\nAlexander Varshavsky California Institute of Technology, Pasadena, CA\n\nAlexander Varshavsky, Ph.D, member of the National Academy of Sciences, Professor, California Institute of Technology, Pasadena, CA\n\nAlexander Varshavsky is a recipient of the Albert Lasker Award for Basic Medical Research, the Wolf Prize in Medicine and the Louisa Gross Horwitz Prize from Columbia University in 2001 for his research on ubiquitination. In 2006 he won the March of Dimes Prize in Developmental Biology and he won the 2007 $1 million Gotham Prize for an original approach to killing cancer cells.\n\nPeter K. Vogt The Scripps Research Institute, La Jolla, CA\n\nPeter K. Vogt, Ph.D, member of the National Academy of Science, Professor, The Scripps Research Institute, La Jolla, CA\n\nDr. Vogt is a Professor in the Department of Molecular and Experimental Medicine at The Scripps Research Institute in La Jolla, California. He has received many awards and honors, including the Gregor Johann Mendel Medal, Charles S. Mott Prize, Ernst Jung Prize for Medicine, Bristol Meyers Award, and ICN International Prize in Virology. Dr. Vogt has been invited as a distinguished lecturer by more than twenty leading research institutions in the US, Europe, and Asia, among them the German Cancer Research Center in Heidelberg for the Meyenburg Foundation Lecture, the Princess Takamatsu Foundation, the Alexander von Humboldt Foundation of the Federal Republic of Germany and the Agency for Science, Technology and Research of Singapore. He was also elected an Honorary Member of the Japanese Cancer Association and received an honorary doctorate from the University of Würzburg. Dr. Vogt is an elected member of many prestigious academies, including the American Academy of Arts and Sciences, the National Academy of Sciences, the Institute of Medicine of the National Academies, and the American Academy of Microbiology. He is the recipient of the 5th Annual Szent-Györgyi Prize for Progress in Cancer Research.\n\nPaul Workman The Institute of Cancer Research, London, UK\n\nPaul Workman, The Institute of Cancer Research, London, UK\n\nZeng Yixin Cancer Center and the State Key Laboratory of Oncology in Southern China, Sun Yat-sen University, Guangzhou, China\n\nDr. Zeng Yixin, Professor and Director, Cancer Center and the State Key Laboratory of Oncology in Southern China, Sun Yat-sen University, Guangzhou, China.\n\nHe was elected as a member of the Chinese Academy of Sciences in 2005. Besides, Professor Zeng also has many other academic positions including the Vice President of the China Anti-Cancer Association, President of the Board of the International Society on Epstein-Barr Virus & Related Diseases (2006-2008), a member of the Third World Academy of Sciences, and a member of the Europe-Asian Academy of Sciences\n\nTwo members of Oncotarget Editorial Board are Nobel Prize winners : Andrew V. Schally ( Physiology or Medicine 1977); Gregg L. Semenza ( Physiology or Medicine 2019)\n\nSince 2013, four members of Oncotarget/Oncoscience/Gerotarget have won the Breakthrough Prize, the highest prize ever: Bert Vogelstein, Michael N. Hall, Alexander Varshavsky, Stephen J. Elledge\n\nIt is with sadness that we share the passing of our Editorial Board Member, Arthur B. Pardee, who died February 24, 2019 at the age of 97.\n\nDr. Pardee (1921-2019), member of the National Academy of Sciences, Professor of Biological Chemistry and Molecular Pharmacology Emeritus, Harvard Medical School, was a renowned cancer biologist who made several groundbreaking discoveries in the mid-20th century that shaped modern molecular biology.\n\nWe have been honored to have Dr. Pardee as a Founding Editor of Oncotarget.\n\nIt is with great sadness that we share the passing of Joseph R. Bertino, MD, the founding Editor of Oncotarget.\n\nFor more than 50 years, Joseph R. Bertino, MD, has devoted his life to improving therapies for cancer and hematologic disorders and has contributed his expertise toward establishing the foundation of modern cancer research. Dr. Bertino is internationally recognized for his role in finding curative treatments for leukemia and lymphoma. He was the past president of The American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO). He received many awards throughout his career including, but not limited to, the AACR Lifetime Achievement in Cancer Research Award, the University of Texas MD Anderson Cancer Center Jeffrey A. Gottlieb Memorial Award, and the LRF Key to the Cure Award and Freundlich Leadership Award."
    }
}